Real-world graft utilization after CTN-1101: a registry-based analysis of haploidentical graft versus umbilical cord blood trends
Open Access
- 18 August 2025
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1369-1376
Abstract
Randomized clinical trials are expensive and not always practice changing. The Blood and Marrow Transplant Clinical Trials Network (CTN) 1101 trial (2012–2018) showed a lower two-year overall survival after umbilical cord blood (UCB) compared to haploidentical graft (haplo) transplants. To quantify the change in graft utilization after the trial’s publication, a cohort of 11,190 U.S. adult HCT recipients selected with inclusion/exclusion criteria similar to CTN-1101’s were analyzed across three time periods: 2010–2012 (pre-study), 2013–2018 (during-study), and 2019–2022 (post-study). We found a significant increase in haplo utilization compared to UCB, with the trend beginning around 2013. Compared to non-Hispanic White, Black recipients were more likely to receive haplo, Asian recipients were less likely, and Hispanic recipients had similar rates. We also expanded our analyses to 61,465 patients to assess haplo and UCB utilization compared to other allogeneic donors. In this cohort, utilization of alternative donor grafts increased when compared to HLA-matched related or unrelated donor grafts for Black, Hispanic, and Asian recipients. Our findings demonstrate practice change toward haplo transplants had begun before the CTN-1101 trial’s publication and continued to significantly increase afterward. HLA-mismatched donors are vital alternative graft sources, allowing patients of all backgrounds to receive HCT.Keywords
Funding Information
- U.S. Department of Health & Human Services | U.S. Public Health Service (U24CA076518, U24CA076518)
- Support is also provided by the Medical College of Wisconsin, NMDP, Gateway for Cancer Research, Pediatric Transplantation and Cellular Therapy Consortium and from numerous commercial entities
- Departmental funding and research funding (to my institution) from Stemline Therapeutics
This publication has 24 references indexed in Scilit:
- Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and AgeJAMA Network Open, 2024
- Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2023
- Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and OutcomesTransplantation and Cellular Therapy, 2022
- Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial OutcomesTransplantation and Cellular Therapy, 2022
- Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood TransplantTransplantation and Cellular Therapy, 2020
- Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood RecipientsTransplantation and Cellular Therapy, 2020
- Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic CancersJAMA Oncology, 2019
- Allogeneic hematopoietic cell transplantation; the current renaissanceBlood Reviews, 2019
- Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in AdultsTransplantation and Cellular Therapy, 2019
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008